Call us 24/7

Expanded access for the treatment of cancers with rearranged during transfection (RET) activation (LIBRETTO-201)


Expanded access for patients with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial.


Accepting new patients

Primary Study Objective(s)

The primary objective of this study is to provide access to selpercatinib for patients with locally advanced or metastatic solid tumors with activating RET alterations (and other evidence of RET activation), who are 18 years of age or older.

Core eligibility

Note: This is only a partial list of eligibility criteria.

Including patients who:

  • Have a fiagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib

Excluding patients who:

  • Are currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor